Jan Beyer-Westendorf, MD,PhD

Head of thrombosis research unit
University Hospital “Carl Gustav Carus”, Technische Universität Dresden, Division of Hematology and Hemostasis, Department of Medicine I Thrombosis Research, Dresden, Saxony, Germany

Jan Beyer-Westendorf
University Hospital Carl Gustav Carus Dresden, Germany
Dr Jan Beyer-Westendorf is Head of the Anticoagulation service and leads the Thrombosis Research Unit at the Department of Medicine I, Division of Haematology at the University Hospital Carl Gustav Carus Dresden, Germany, and Associate Professor of Internal Medicine at the Technical University of Dresden. From 2016 - 2019 he has served as a senior lecturer in thrombosis and haemostasis at King’s College London, UK.
After completing his residency in internal medicine at the University Hospital Carl Gustav Carus Dresden in 2005, Dr Beyer-Westendorf went on to specialise in intensive care medicine, vascular medicine and thrombosis/haemostasis. His research interests mainly focus on venous thromboembolism, atrial fibrillation, anticoagulant therapies and bleeding management.
Dr Beyer-Westendorf has served on the steering committee of numerous clinical trials in cardiovascular medicine and has participated as Principal Investigator in phase II-IV trials evaluating the non-vitamin K antagonist oral anticoagulants. Since 2011 he runs a regional prospective registry looking at the efficacy, safety and management aspects of oral anticoagulants in daily practice, which currently has over 5000 enrolled patients.
Dr Beyer-Westendorf has authored or co-authored more than 200 well-received publications in peer-reviewed international journals, as well as many book chapters. He is a reviewer for several international journals, including the NEJM, Lancet, BMJ, Blood, European Heart Journal, JACC, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, and Thrombosis Research.

Presentation(s):

• SS 12.5 - The Right Dose At the Right Time: Optimising Treatment Dosing and Duration in VTE

  Sunday, July 10, 2022
  2:05 PM – 2:20 PM

• OC 24.2 - VALIDATION OF A TREATMENT DECISION ALGORITHM FOR THE USE OF ANDEXANET ALFA IN ACUTE LIFE-THREATENING BLEEDING FROM DIRCT FACTOR Xa INHIBITORS

  Sunday, July 10, 2022
  3:00 PM – 3:15 PM

• SS 26.2 - Case 1: Assessing Risk

  Tuesday, July 12, 2022
  1:25 PM – 1:45 PM

• SS 26.5 - Panel Discussion: Summary of Key Points and Wrap-up

  Tuesday, July 12, 2022
  2:20 PM – 2:30 PM

• OC 71.4 - Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY

  Wednesday, July 13, 2022
  11:00 AM – 11:15 AM